Zejula (niraparib)

News alerts, weekly reports and conference planners

Company:

GSK, J&J, Medison, Takeda, ZAI Lab

Drug class:

PARP inhibitor

Related drugs:

No biomarker	Fallopian Tube Cancer	No biomarker	Fallopian Tube Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
No biomarker	Peritoneal Cancer	No biomarker	Peritoneal Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
BRCA1 mutation	Peritoneal Cancer	BRCA1 mutation	Peritoneal Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
BRCA2 mutation	Peritoneal Cancer	BRCA2 mutation	Peritoneal Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
BRCA1 mutation	Fallopian Tube Cancer	BRCA1 mutation	Fallopian Tube Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
BRCA2 mutation	Fallopian Tube Cancer	BRCA2 mutation	Fallopian Tube Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
HRD	Peritoneal Cancer	HRD	Peritoneal Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
HRD	Fallopian Tube Cancer	HRD	Fallopian Tube Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
HRD	Ovarian Cancer	HRD	Ovarian Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
BRCA1 mutation	Prostate Cancer	BRCA1 mutation	Prostate Cancer	niraparib Sensitive: A2 - Guideline niraparib Sensitive : A2	niraparib Sensitive: A2 - Guideline niraparib Sensitive : A2
BRCA2 mutation	Prostate Cancer	BRCA2 mutation	Prostate Cancer	niraparib Sensitive: A2 - Guideline niraparib Sensitive : A2	niraparib Sensitive: A2 - Guideline niraparib Sensitive : A2
No biomarker	Peritoneal Cancer	No biomarker	Peritoneal Cancer	bevacizumab + niraparib Sensitive: A2 - Guideline bevacizumab + niraparib Sensitive : A2	bevacizumab + niraparib Sensitive: A2 - Guideline bevacizumab + niraparib Sensitive : A2
No biomarker	Fallopian Tube Cancer	No biomarker	Fallopian Tube Cancer	bevacizumab + niraparib Sensitive: A2 - Guideline bevacizumab + niraparib Sensitive : A2	bevacizumab + niraparib Sensitive: A2 - Guideline bevacizumab + niraparib Sensitive : A2
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	bevacizumab + niraparib Sensitive: A2 - Guideline bevacizumab + niraparib Sensitive : A2	bevacizumab + niraparib Sensitive: A2 - Guideline bevacizumab + niraparib Sensitive : A2
HRD + BRCA wild-type	Ovarian Cancer	HRD + BRCA wild-type	Ovarian Cancer	niraparib Sensitive: A2 - Guideline niraparib Sensitive : A2	niraparib Sensitive: A2 - Guideline niraparib Sensitive : A2
BRCA2 mutation	HER2 Negative Breast Cancer	BRCA2 mutation	HER2 Negative Breast Cancer	niraparib Sensitive: B - Late Trials niraparib Sensitive : B	niraparib Sensitive: B - Late Trials niraparib Sensitive : B
BRCA1 mutation	HER2 Negative Breast Cancer	BRCA1 mutation	HER2 Negative Breast Cancer	niraparib Sensitive: B - Late Trials niraparib Sensitive : B	niraparib Sensitive: B - Late Trials niraparib Sensitive : B
HRD	Prostate Cancer	HRD	Prostate Cancer	niraparib Sensitive: B - Late Trials niraparib Sensitive : B	niraparib Sensitive: B - Late Trials niraparib Sensitive : B
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	niraparib + dostarlimab-gxly Sensitive: B - Late Trials niraparib + dostarlimab-gxly Sensitive : B	niraparib + dostarlimab-gxly Sensitive: B - Late Trials niraparib + dostarlimab-gxly Sensitive : B
BRCA2 mutation	Triple Negative Breast Cancer	BRCA2 mutation	Triple Negative Breast Cancer	niraparib Sensitive: C1 - Off-label niraparib Sensitive : C1	niraparib Sensitive: C1 - Off-label niraparib Sensitive : C1
BRCA1 mutation	Triple Negative Breast Cancer	BRCA1 mutation	Triple Negative Breast Cancer	niraparib Sensitive: C1 - Off-label niraparib Sensitive : C1	niraparib Sensitive: C1 - Off-label niraparib Sensitive : C1
BRCA1 mutation	Endometrial Cancer	BRCA1 mutation	Endometrial Cancer	niraparib Sensitive: C1 - Off-label niraparib Sensitive : C1	niraparib Sensitive: C1 - Off-label niraparib Sensitive : C1
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	pembrolizumab + niraparib Sensitive: C2 – Inclusion Criteria pembrolizumab + niraparib Sensitive : C2	pembrolizumab + niraparib Sensitive: C2 – Inclusion Criteria pembrolizumab + niraparib Sensitive : C2
HRD + BRCA1 mutation	Ovarian Cancer	HRD + BRCA1 mutation	Ovarian Cancer	niraparib Sensitive: C2 – Inclusion Criteria niraparib Sensitive : C2	niraparib Sensitive: C2 – Inclusion Criteria niraparib Sensitive : C2
HRD	Ovarian Cancer	HRD	Ovarian Cancer	bevacizumab + niraparib Sensitive: C2 – Inclusion Criteria bevacizumab + niraparib Sensitive : C2	bevacizumab + niraparib Sensitive: C2 – Inclusion Criteria bevacizumab + niraparib Sensitive : C2
ATM mutation	Colorectal Cancer	ATM mutation	Colorectal Cancer	niraparib Sensitive: C3 – Early Trials niraparib Sensitive : C3	niraparib Sensitive: C3 – Early Trials niraparib Sensitive : C3
BRCA1 mutation	Triple Negative Breast Cancer	BRCA1 mutation	Triple Negative Breast Cancer	pembrolizumab + niraparib Sensitive: C3 – Early Trials pembrolizumab + niraparib Sensitive : C3	pembrolizumab + niraparib Sensitive: C3 – Early Trials pembrolizumab + niraparib Sensitive : C3
BRCA2 mutation	Triple Negative Breast Cancer	BRCA2 mutation	Triple Negative Breast Cancer	pembrolizumab + niraparib Sensitive: C3 – Early Trials pembrolizumab + niraparib Sensitive : C3	pembrolizumab + niraparib Sensitive: C3 – Early Trials pembrolizumab + niraparib Sensitive : C3
HRD + BRCA1 mutation	Peritoneal Cancer	HRD + BRCA1 mutation	Peritoneal Cancer	niraparib Sensitive: C3 – Early Trials niraparib Sensitive : C3	niraparib Sensitive: C3 – Early Trials niraparib Sensitive : C3

Zejula (niraparib)

Associations
(80)

Associations
(80)

Zejula (niraparib)

Associations(80)

Associations(80)

Associations
(80)

Associations
(80)